JP2025510786A - 視神経脊髄炎（ＮＭＯ）の新規治療法としてのＭＨＣ Ｉｂを介したアクアポリン４（ＡＱＰ４）特異的免疫抑制 - Google Patents

視神経脊髄炎（ＮＭＯ）の新規治療法としてのＭＨＣ Ｉｂを介したアクアポリン４（ＡＱＰ４）特異的免疫抑制 Download PDF

Info

Publication number
JP2025510786A
JP2025510786A JP2024556458A JP2024556458A JP2025510786A JP 2025510786 A JP2025510786 A JP 2025510786A JP 2024556458 A JP2024556458 A JP 2024556458A JP 2024556458 A JP2024556458 A JP 2024556458A JP 2025510786 A JP2025510786 A JP 2025510786A
Authority
JP
Japan
Prior art keywords
recombinant polypeptide
amino acid
human
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510786A5 (https=
Inventor
ブルッテル，ヴァレンティン
ヴィシュフーゼン，イェルク
ママタ ジャヤラム，シュリヤ
アーサン，ファディル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2025510786A publication Critical patent/JP2025510786A/ja
Publication of JP2025510786A5 publication Critical patent/JP2025510786A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024556458A 2022-03-24 2023-03-24 視神経脊髄炎（ＮＭＯ）の新規治療法としてのＭＨＣ Ｉｂを介したアクアポリン４（ＡＱＰ４）特異的免疫抑制 Pending JP2025510786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164161.6A EP4249062A1 (en) 2022-03-24 2022-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EP22164161.6 2022-03-24
PCT/EP2023/057684 WO2023180549A1 (en) 2022-03-24 2023-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Publications (2)

Publication Number Publication Date
JP2025510786A true JP2025510786A (ja) 2025-04-15
JP2025510786A5 JP2025510786A5 (https=) 2026-02-20

Family

ID=81325683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556458A Pending JP2025510786A (ja) 2022-03-24 2023-03-24 視神経脊髄炎（ＮＭＯ）の新規治療法としてのＭＨＣ Ｉｂを介したアクアポリン４（ＡＱＰ４）特異的免疫抑制

Country Status (12)

Country Link
US (1) US20250205322A1 (https=)
EP (2) EP4249062A1 (https=)
JP (1) JP2025510786A (https=)
KR (1) KR20240164796A (https=)
CN (1) CN119110810A (https=)
AU (1) AU2023237632A1 (https=)
CA (1) CA3250911A1 (https=)
CL (1) CL2024002725A1 (https=)
CO (1) CO2024012332A2 (https=)
IL (1) IL314754A (https=)
MX (1) MX2024011666A (https=)
WO (1) WO2023180549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061917A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234017B2 (en) * 2012-12-11 2016-01-12 The Regents Of The University Of California Aquaporin-4 peptide compositions and methods of use thereof
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US20230114434A1 (en) * 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders

Also Published As

Publication number Publication date
WO2023180549A1 (en) 2023-09-28
CA3250911A1 (en) 2023-09-28
EP4499231A1 (en) 2025-02-05
EP4249062A1 (en) 2023-09-27
AU2023237632A1 (en) 2024-08-15
CO2024012332A2 (es) 2024-09-30
MX2024011666A (es) 2024-09-27
CN119110810A (zh) 2024-12-10
US20250205322A1 (en) 2025-06-26
KR20240164796A (ko) 2024-11-20
IL314754A (en) 2024-10-01
CL2024002725A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
JP2023511417A (ja) 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法
CN115702162A (zh) 用于治疗多发性硬化的肽和方法
KR20210041559A (ko) 다발경화증에서의 면역우세 단백질 및 단편
JP2025510786A (ja) 視神経脊髄炎（ＮＭＯ）の新規治療法としてのＭＨＣ Ｉｂを介したアクアポリン４（ＡＱＰ４）特異的免疫抑制
JP2026065089A (ja) Ｄｃａｆ４ｌ２特異的ｔ細胞受容体
JP2025513720A (ja) 多発性硬化症及び抗ＭＯＧ抗体性疾患のための新規治療法としてのＭＨＣ Ｉｂ仲介ミエリン特異的免疫抑制
CA2897655C (en) Antigen processing-independent epitopes (apitopes) of myelin oligodendrocyte glycoprotein
JPH10501888A (ja) 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
AU2024346292A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
JP2025514872A (ja) パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導
US20250205323A1 (en) Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
TW202519540A (zh) MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療
Seta et al. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals
CN110862449B (zh) 衍生自ssx的肿瘤抗原短肽
Cimons The Impact of Lineage-Specifying Transcription Factor Overexpression on Car T Cell Function
Gonzalez Basigin as an Immune Mediator in the CNS
Frenati Role of CYBR, a cytohesin binder and regulator scaffold protein, in cell-mediated immune response in vivo
Ray et al. An Increase in Tolerogenic Dendritic Cell and Natural T Regulatory Cell Numbers During EAE in Rras−/− Mice Results in Attenuated Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241009

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260212